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Abstract
Background: The presence of monocyte-macrophage lineage cells in rejecting kidney transplants is associated with worse
graft outcome. At present, it is still unclear how the monocyte-macrophage related responses develop after transplantation.
Here, we studied the dynamics, phenotypic and functional characteristics of circulating monocytes during the first 6 months
after transplantation and aimed to establish the differences between kidney transplant recipients and healthy individuals.
Methods: Phenotype, activation status and cytokine production capacity of classical (CD14++CD162), intermediate
(CD14++CD16+) and non-classical (CD14+CD16++), monocytes were determined by flow cytometry in a cohort of 33 healthy
individuals, 30 renal transplant recipients at transplantation, 19 recipients at 3 months and 16 recipients at 6 months after
transplantation using a cross-sectional approach.
Results: The percentage of both CD16+ monocyte subsets was significantly increased in transplant recipients compared to
healthy individuals, indicative of triggered innate immunity (p#0.039). Enhanced production capacity of tumor necrosis
factor-a, interferon-c and interleukin-1b was observed by monocytes at transplantation compared to healthy individuals.
Remarkably, three months post-transplant, in presence of potent immunosuppressive drugs and despite improved kidney
function, interferon-c, tumor necrosis factor-a and interleukin-10 production capacity still remained significantly increased.
Conclusion: Our data demonstrate a skewed balance towards pro-inflammatory CD16+ monocytes that is present at the
time of transplantation and retained for at least 6 months after transplantation. This shift could be one of the important
drivers of early post-transplant cellular immunity.
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Introduction
Monocyte-macrophage lineage cells next to T-cells are the
predominant cell types infiltrating acutely rejecting kidney
transplants [1,2]. The intra-graft presence of macrophages
(MWs) during rejection is associated with worse graft outcome.
Although T-cells are known to be required for acute rejection [3–
5], the degree to which monocytes and MWs contribute to this
process remains incompletely defined.
MWs are heterogeneous with established roles in tissue injury,
homeostasis, remodelling and repair [6,7]. MWs can be detected in
large numbers in kidney grafts undergoing ischemia/reperfusion
injury, during T–cell and antibody–mediated rejection. MW
infiltration correlated with poor rejection prognosis due to their
contribution to early and late inflammatory injury [8,9]. Depletion
of infiltrating MWs reduced histological features of acute rejection
and led to improvement of transplant function in rodent models of
kidney transplantation (Tx) [10,11]. In humans, treatment with
vitamin D reduced the number of graft infiltrating MWs and was
associated with increased transplant survival [12]. On the other
hand, a protective role was also ascribed to so-called regulatory
MWs [13]. A week prior to kidney Tx regulatory MWs, which were
able to eliminate activated T-cells in vitro, were transfused into 2
patients. After 24 weeks these patients needed only low-dose
tacrolimus monotherapy to preserve their grafts from rejection
[13]. In line, administration of MWs with specific wound healing
and anti-inflammatory phenotypes reduced histological and
functional markers of kidney injury in rodents [14,15].
Monocytes can be subdivided into three phenotypically and
functionally distinct subpopulations based on the expression of the
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lipopolysaccharide (LPS) receptor, CD14, and the Fcc receptor
III, CD16 [16,17]. In healthy individuals approximately 80–90%
of monocytes are highly CD14 positive and CD16 negative
(CD14++CD162): classical monocytes. The remaining 10–20% of
monocytes are CD16 positive, which are further subdivided into
CD14++CD16+ and CD14+CD16++ cells, intermediate and non-
classical monocytes respectively [17]. These monocyte subsets
have different chemokine-receptor expression profiles [18].
Important monocytic functions, such as phagocytosis, antigen
presentation and cytokine production, are also differently regulat-
ed in the monocyte subpopulations [19–21]. The monocyte subset
composition is altered in several pathologic conditions, including
inflammatory and infectious diseases [22] and in coronary heart
disease [23]. In kidney transplant recipients, CD14+CD16+
monocytes were associated with subclinical atherosclerosis [24].
In addition, higher numbers of pro-inflammatory CD14+CD16+
monocytes were detected in patients with end-stage renal disease
compared to healthy controls [25–28]. Monocyte infiltration and
specifically glomerular monocytes were associated with graft
dysfunction and poor graft outcome [29,30]. Furthermore,
monocytic infiltrates seemed to drive the acute rejection in T-
cell-depleted, alemtuzumab-treated kidney transplant recipients
[31].
At present, a paucity of data exists regarding the phenotype,
dynamics and kinetics of circulating monocytes in relation to Tx
and post-transplant complications. We hypothesised that at the
time of Tx monocyte subset composition will reflect a higher
inflammatory state returning to levels comparable with healthy
individuals post-Tx. In this study we determined the dynamics,
phenotypic and functional characteristics of peripheral blood
monocyte subsets in kidney transplant recipients compared to
healthy individuals using a cross-sectional approach.
Materials and Methods
Ethics Statement
This study has been approved by the Ethical Committee of the
ErasmusMC. All patients have signed written informed consent
following the guidelines of the Ethical Committee of the
ErasmusMC.
Patient Characteristics
Whole blood was collected from different groups consisting of
33 healthy individuals (transplant donors), 30 renal recipients at
the time of Tx, 19 patients 3 months after Tx, and from 16
patients 6 months after Tx in a cross-sectional approach. All
patients were treated homogenously with basiliximab (simulectH)
as induction therapy and received triple maintenance immuno-
suppressive drugs consisting of corticosteroids, calcineurin inhib-
itors and mycophenolate mofetil according to our local protocol.
Corticosteroids (started at 20 mg daily dose) were tapered off to
zero at four months after Tx. In addition, the dosing of calcineurin
inhibitors was adjusted using the drug trough levels to achieve the
pre-defined target trough levels according to protocol. Mycophe-
nolate mofetil was given at a fixed dose. Clinical and immuno-
logical characteristics of kidney transplant recipients and kidney
donors are listed in Table 1.
Phenotype Characterisation and Activation
To determine the phenotype and activation status of the
monocytes, 100 ml whole blood was incubated with conjugated
primary antibodies CD3-Amcyan (BD Biosciences), CD3-PE,
CD14-Pacfic Blue, CD16-PE-Cy7, CD20-PE, CD56-PE, HLA-
DR-APC-Cy7, CD40-FITC, CD80-FITC (all Biolegend), and
CD56-APC (eBioscience) for 30 minutes at 4uC. Subsequently the
blood was incubated for 10 minutes at room temperature with
FACS lysing solution (BD Biosciences) to remove erythrocytes.
The cells were washed and analysed using flow cytometry
(FACSCanto II, BD Biosciences) and FACSDiva software.
Monocytes were characterised based on forward/sideward scatter,
lack of expression of CD3, CD20 and CD56 and expression of
CD14 and CD16. Conjugated antibodies were used as negative
isotype controls. Absolute cell numbers were determined by flow
cytometry using TruecountTM tubes (BD Biosciences).
Intracellular Cytokine Production
Peripheral blood mononuclear cells (PBMCs) were isolated from
heparinised blood using Ficoll-Hypaque density gradient (Lym-
phoprepTM). PBMCs were pre-stimulated with 20 ng/ml interfer-
on-gamma (IFN-c) (U-Cytech) for 2 hours at 37uC followed by
overnight treatment with 100 ng/ml LPS (Sigma-Aldrich) and
golgiplug (BD Biosciences). After this stimulation ethylenediamine-
tetraacetic acid was added to the PBMCs for 15 min and cells
were washed. Next, extracellular markers, CD3-PE, CD20-PE,
CD56-PE, CD14-Pacific Blue and CD16-PE-Cy7, were stained as
described above. After treatment with FACS lysing solution,
PBMCs were treated with FACS Permeabilizing solution 2 (BD
Biosciences) for 15 minutes. Subsequently, conjugated primary
antibodies to tumor necrosis factor-alpha (TNF-a)-Percp-Cy5.5,
Interleukin-1b (IL-1b)-FITC, IFN-c-APC-Cy7, IL-6-APC and IL-
10-FITC (all Biolegend) were added to determine intracellular
cytokine production. The cells were washed and analysed using
flow cytometry (FACSCanto II, BD Biosciences) and FACSDiva
software. The entire monocyte population was characterised based
on forward/sideward scatter, lack of expression of CD3, CD20
and CD56 and expression of CD14 and CD16. Conjugated
antibodies were used as negative isotype controls. To exclude the
possibility of IFN-c uptake by monocytes as the reason for
increased production capacity of IFN-c by IFN-c and LPS-
stimulated monocytes, we also used LPS alone to stimulate
monocytes.
Statistical Analysis
Statistical analysis was performed using Kruskal Wallis test and
one-way ANOVA with Bonferroni correction in SPSS (15.0.0,
Chicago, USA). A p-value ,0.05 was considered significant. Data
are presented as median6SEM unless otherwise stated.
Results
Dynamics of Monocyte Subsets in Kidney Transplant
Recipients
The absolute number of monocytes was similar between
transplant recipients at the time of transplantation and healthy
controls (Figure 1). The number of monocytes significantly
decreased after Tx compared to both healthy controls and
recipients at the time of Tx (42629.5 cells/ml at 3 months and
283628.9 cells/ml at 6 months vs 538648.4 cells/ml at the time of
Tx and 458653.5 cells/ml in healthy controls). A trend towards
recovery of monocyte number was observed 6 months after Tx.
CD14 and CD16 cell surface expression revealed that monocyte
subset composition was altered at the time of Tx and post-
transplant as compared to healthy controls (Figure 2A–D). At the
time of Tx the percentage of CD14++CD162 monocytes was
significantly decreased in comparison to controls (76.6%62% vs.
82.4%60.8%, p=,0.001) (Figure 2E), while the CD16+
monocyte subsets were significantly increased. This rise in
CD16+ monocytes was due to a significant increase in both
Monocyte Subsets Dynamics after Transplantation
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CD14++CD16+ (10.462%, vs. 5.460.4%, p=,0.001) and
CD14+CD16++ subsets (11.862%, vs. 8.860.6%, p=,0.001)
(Figure 2G and I). No difference in absolute number of
CD14++CD162 subset could be observed between healthy
controls and recipients at time of Tx (377649.1 vs 380.6639.4)
(Figure 2F). In contrast, absolute numbers of CD14++CD16+ and
CD14+CD16++ monocytes were significantly increased compared
to controls (5369.8 and 60.268.5 vs 25.562.5 and 44.564.3)
(Figure 2H and J).
Surprisingly, even under potent triple immunosuppressive
therapy and despite recovery of kidney function after Tx
(Table 1), sustained quantitative and qualitative changes in
monocyte subsets remained present, distinguishing transplant
population from healthy individuals. Both 3 and 6 months after
Tx the percentage of CD14++CD162monocytes was significantly
lower compared to healthy controls (74.262.4% and 73.662.1%
vs 82.4%60.8%, p=,0.001), while a sustained significant rise in
the percentage of CD16+ monocytes was observed at both time
points post-Tx (Figure 2G and I, p=,0.001). Again both
CD14++CD16+ and CD14+CD16++ monocyte subsets contrib-
uted to this significant rise in frequency (8.960.9% and
11.961.2% at 3 months, 11.861.2% and 15.261.2% at 6
months vs 5.460.4% and 8.860.6% respectively, p=,0.039). In
our cohort, the total number of monocytes was decreased after Tx
in comparison to healthy individuals. The number of
CD14++CD162 monocytes was significantly lower at post-Tx
time points compared to healthy controls (121.6623.5 at 3 months
and 195.6622.7 at 6 months vs 377.4649.1, p =,0.003).
However, the number of CD16+ monocytes, both
CD14++CD16+ (6.863.9 at 3 months and 37.165.6 at 6 months
vs 25.562.5) and CD14+CD16++ (22.365.6 at 3 months and
47.565.7 at 6 months vs 44.564.3) subsets, remained constant
after Tx and were comparable to those found in healthy controls
(Figure 2H and J).
Thus, although the absolute number of monocytes decreased in
the post-transplant period, subset distribution remained constant
and similar to the skewed distribution of monocyte subsets present
at the time of Tx, with a relative over-representation of CD16+
monocytes.
Expression of Co-stimulatory Molecules by Monocyte
Subsets in Kidney Transplant Recipients
In order to determine the activation status of circulating
monocytes, cell surface expression of HLA-DR and co-stimulatory
Table 1. Clinical and immunological characteristics of kidney transplant recipients.
Characteristics
Healthy controls
N=33
Time of Tx
N=30
3 months
post-Tx N=19
6 months
post-Tx N=16
Age (median (year), range) 51 (25–73) 59 (23–77) 59 (23–69) 62 (23–76)
Gender (% male) 42% 73% 68% 75%
PreTx CMV status (% positive) 48% 53% 58% 43.75%
Dialysis (number of patients, %) 19 (63.3%) 10 (52.6%) 9 (56.3%)
Pre-emptive transplantation 11 (36.7%) 9 (47.4%) 7 (43.8%)
Transplantation type (%)
Living donor, related 11 (36.7%) 8 (42.1%) 7 (43.8%)
Living donor, unrelated 19 (63.3%) 11 (57.9%) 9 (56.3%)
Primary disease (number of patients, %)
Polycystic kidney disease 5 (16.7%) 2 (10,5%) 2 (12.5%)
Diabetic nephropathy 3 (10%) 2 (10.5%) 3 (18.8%)
Hypertension 9 (30%) 8 (42.1%) 6 (37.5%)
IgA nephropathy 2 (6.7%) 2 (10.5%) 1 (6.3%)
Reflux nephropathy 1 (3.3%) 1 (5.3%) 0 (0%)
Glomerulonephritis 3 (10%) 1 (5.3%) 1 (6.3%)
Others 7 (23.3%) 3 (15.8%) 3 (18.8%)
HLA mismatches total (median, range) 3 (0–6) 3 (1–5) 3 (2–5)
Class I mismatches 2 (0–4) 2 (0–4) 2 (1–3)
Class II mismatches 1 (0–2) 1 (0–2) 1 (1–2)
Warm ischemia (median (min), range) 19 (11–55) 19 (12–35) 20 (12–35)
Kidney Function: GFR (ml/min, median, range)
GFR at time of Tx 8 (2–21) 7 (2–14) 7 (5–17)
GFR at 3 months postTx 50 (27–82) 55 (26–90) 54.5 (33–76)
GFR at 6 months postTx 47 (19–69) 54 (19–81) 63 (34–81)
Kidney Function: Serum creatinine (mmol/l, median, range)
Creatinine at time of Tx 610.5 (236–1830) 672 (375–1456) 670.5 (319–885)
Creatinine at 3 months postTx 126 (69–379) 122 (46–177) 122 (85–195)
Creatinine at 6 months postTx 137 (91–319) 114 (85–233) 107.5 (69–188)
doi:10.1371/journal.pone.0070152.t001
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molecules, CD80 and CD40 was measured. In all groups HLA-
DR cell surface expression, as measured by mean fluorescence
index (MFI), was significantly higher in CD14++CD16+ mono-
cytes compared to CD14++CD162 and CD14+CD16++
(Figure 3A, p=,0.002). The level of HLA-DR cell surface
expression was comparable between healthy donors and recipients
at the time of Tx (Figure 3A). In contrast, the percentage of HLA-
DR positive monocytes was significantly higher in patients at the
time of Tx compared to healthy controls (Figure 3B, p = 0.002).
Interestingly, after Tx a decrease in HLA-DR cell surface
expression level was observed in all monocyte subsets compared
to the time of Tx, reaching significance in classical and non-
classical monocytes at 3 months compared to the time of Tx, and
in the classical and intermediate monocyte subsets at 6 months
after Tx.
The pattern of CD80 expression was similar in all groups tested,
with a significantly higher expression of CD80 in CD14++CD16+
monocytes compared to CD14++CD162 and CD14+CD16++
(Figure 3C, p=,0.05). Both CD80 cell surface expression level, as
measured by MFI, and the percentage of CD80 positive
monocytes did not differ between transplant recipients at time of
Tx and healthy controls (Figure 3C and D). A trend towards
higher CD80 cell surface expression was seen during the post-
transplant period compared to the time of Tx reaching statistical
significance in CD14++CD162 monocytes 6 months after Tx
(p = 0.009).
Similar to CD80, no difference was observed in both percentage
of CD40 positive monocytes and CD40 cell surface expression
between healthy controls and kidney transplant recipients in all
different subsets tested (Figure 3E and F). The cell surface
expression level of CD40, displayed a trend towards higher
expression at the time of Tx and 3 months thereafter compared to
healthy controls. At 6 months, CD40 expression was decreased but
still remained comparable to healthy controls.
Intracellular Cytokine Production by Monocytes in Kidney
Transplant Recipients
Next, we hypothesized that the capacity of monocytes to
produce pro- and anti- inflammatory cytokines would be affected
by post-transplant early immunity and the use of immunosup-
pressive drugs. Therefore we measured the production of pro-
inflammatory cytokines TNF-a, IFN-c, IL-6 and IL-1b, and anti-
inflammatory cytokine IL-10 by monocytes obtained at the time of
Tx and at 3 months post-transplant (Figure 4). Representative
FACS plots of unstimulated and stimulated monocytes and the
isotype controls are depicted in Figures S1–7.
The percentage of TNF-a producing monocytes was signifi-
cantly increased in patients at the time of Tx compared to healthy
controls (39.2%63.3 vs. 24.8%63.9, p= 0.036) (Figure 4A).
Remarkably, despite recovery of kidney function and use of
immunosuppressive drugs 3 months after Tx, the percentage of
TNF-a producing monocytes still remained significantly higher in
comparison to healthy controls (34.2%63.8 vs. 24.8%63.9,
p = 0.032). To our surprise, kidney transplant recipients had a
significantly higher percentage of IFN-c producing monocytes not
only at the time of Tx but also 3 months thereafter (32.8%62.8 vs.
18.8%62.7 p= 0.03 and 30.3%63.9 vs. 18.8%62.7 p= 0.006)
(Figure 4B). This indicates a higher potential of monocytes to
produce dominant pro-inflammatory cytokines that is retained
during the first 3 months after Tx and not diminished by
immunosuppression. Stimulation with LPS alone also significantly
increased the percentage of IFN-c positive monocytes, indicating
that the increased IFN-c production capacity by monocytes was
not due to uptake from the supernatant (Figure S8).
The production of IL-6 did not differ significantly between
recipients and healthy controls at the time points measured
(Figure 4C). A significantly higher percentage of monocytes
produced IL-1b in recipients at the time of Tx compared to
healthy controls (22.4%62.8 vs.10.3%62.6, p = 0.005)
(Figure 4D). Three months after Tx the percentage of IL-1b
producing monocytes was back to healthy control levels
(11.9%62.3 vs 10.3%62.6). Although a bimodal distribution
could be observed in IL-10 producing monocytes after Tx, which
might be attributable to the limited numbers tested, the percentage
IL-10 producing monocytes was significantly higher 3 months
post-Tx compared to both healthy controls and recipients at the
time of Tx (7.1%61.4 vs 1.4%60.2 and 3.1%60.7, p= 0.001)
(Figure 4E). Importantly, no difference in percentage of IL-10
producing monocytes was observed between recipients at the time
of Tx and healthy controls, indicating their preserved IL-10
producing capacity.
Discussion
Our study reveals that the monocyte subset composition is
significantly altered in kidney transplant recipients as compared to
healthy individuals at pre- and post-Tx time points. The balance is
skewed towards the pro-inflammatory intermediate and non-
classical subsets for at least six months after Tx even though the
total number of monocytes is decreased. At Tx, the monocytes
possess the potential to produce significantly higher levels of
dominant pro-inflammatory cytokines IL-1b, TNF-a and IFN-c.
Even in the presence of potent triple immunosuppression,
decreased total number of monocytes and despite recovered
kidney function, the cytokine production capacity of monocytes
remains higher than the healthy control group during the
examined post-Tx period. This shift in dynamics and character-
istics of monocyte subsets could be one of the important cellular
drivers of early post-transplant immunity.
Figure 1. Decreased absolute number of monocytes after
kidney transplantation. The absolute number of monocytes is
significantly decreased after Tx compared to healthy controls and
recipients at the time of Tx. Healthy controls (n = 28), recipient at the
time of Tx (n = 30), recipient 3 months post-Tx (n = 19) and 6 months
post-Tx (n = 15).
doi:10.1371/journal.pone.0070152.g001
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In line with our results, the presence of an increased percentage
of intermediate and non-classical monocytes in end-stage kidney
disease patients undergoing dialysis has been reported
[25,26,28,32,33] Scherberich et al. found an increase in the
monocyte subset co-expressing CD14 with CD16 in patients with
chronic renal failure [27]. The authors investigated the effect of
different immunosuppressive regimens on the frequency of
intermediate and non-classical monocytes. No difference was
observed between the different medication groups [27]. This is
notable, since glucocorticoids are cornerstone drugs used after Tx
and a preferential decrease of the CD14+CD16+ monocyte
population by glucocorticoids has been described [34]. Ulrich
et al. showed a significant decrease in the percentage of
CD14+CD16+ monocytes in kidney transplant recipients receiv-
ing methylprednisolone in combination with other immunosup-
pressive drugs compared to haemodialysis patients [24]. We could
not confirm steroid-induced effects in our population, as patients
were treated homogeneously with prednisone up to 4 months after
Tx. Differences in dosing or relative overrepresentation of
intermediate and non-classical monocytes might explain these
different observations despite their higher sensitivity for cortico-
steroids.
We measured monocyte activation status based on the
expression of co-stimulatory molecules. Compared to healthy
controls, the percentage of HLA-DR positive monocytes was
higher at the time of Tx indicating a triggered activation status.
Figure 2. A shift towards CD16+ monocyte subsets in kidney transplant recipients. Representative FACS-plots of CD14/CD16 staining are
shown: (A) healthy controls, (B) recipient at the time of Tx, (C) recipient 3 months post-Tx and (D) 6 months post-Tx. The percentage of
CD14++CD162 monocytes (E) was significantly decreased at time of Tx in comparison to healthy controls, while the absolute number of
CD14++CD16– monocytes (F) remained the same. The increased frequency of CD16+ monocytes, and the concomitant decrease in the classical
subset were retained during the post-transplant period. The absolute number of CD14++CD162 monocytes was significantly decreased in the post-
transplant period, while the numbers of CD16+ intermediate-non classical monocytes were not altered compared to healthy individuals. The
percentage (G and H) and absolute number (I and J) of CD16+ intermediate-non classical monocytes were significantly increased at the time of Tx
compared to healthy individuals. Healthy controls (n = 33), recipients at Tx (n = 30), 3 months post-Tx (n = 19), and 6 months post-Tx (n = 15).
doi:10.1371/journal.pone.0070152.g002
Figure 3. Expression of co-stimulatory molecules by monocytes in kidney transplant recipients. (A) HLA-DR expression was decreased
after Tx compared to recipients at the time of Tx. (B) The percentage of HLA-DR positive monocytes was significantly increased at the time of Tx
compared to healthy controls. CD80 expression (C) and the percentage of CD80 positive monocytes (D) did not differ between recipients at time of
Tx and healthy controls. The CD40 expression (E) and the percentage of CD40 expressing monocytes (F) were similar in all the groups tested. Healthy
controls (n = 33), recipients at Tx (n = 30), 3 months post-Tx (n = 19), and 6 months post-Tx (n = 16).
doi:10.1371/journal.pone.0070152.g003
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Surprisingly, HLA-DR and CD40 cell surface expression in the
post-transplant period was comparable to healthy controls,
indicating that immunosuppression did not lower the activation
status of monocytes beyond healthy control levels. A trend towards
higher CD80 expression was visible in the post-transplant period,
which might imply a higher pro-inflammatory set-point compared
to healthy controls.
Even though the absolute number of monocytes was decreased
after Tx, the percentage of TNF-a and IFN-c producing
monocytes was significantly increased in kidney transplant
recipients at the time of Tx and at 3 months post-transplant
compared to healthy controls. Both stimulation with IFN-c and
LPS or LPS alone resulted in an increase in the percentage of IFN-
c producing monocytes, which is a re-confirmation of the presence
of the higher production capacity of IFN-c by monocytes in our
population of interest. Even though the CD14 staining patterns
are somewhat distorted, probably due to the stimulation, apoptosis
and/or formed clumps, it is clear that the cytokine production is
enhanced after stimulation. We also demonstrated that IFN-c can
be produced by monocytes obtained from kidney transplant
recipients using stimulation protocols (IFN-c and LPS or LPS
alone) at both mRNA and protein level (unpublished data).
Although IFN-c production by human monocyte-derived MWs
and dendritic cells were described previously [35–37], a recently
published report demonstrated production of high IFN-c levels by
human monocytes in the presence of IL-2 and the bisphosphonate
Figure 4. Production of cytokines by monocytes in kidney transplant recipients. Production of cytokines was tested after stimulation of
freshly isolated PBMCs of healthy controls, recipients at the time of Tx and recipients at 3 months after Tx with IFN-c and LPS in the presence of
golgiplug. The entire monocyte population was determined based on forward/sideward scatter, lack of expression of CD3, CD20 and CD56 and
expression of CD14 and CD16. The percentage of (A) TNF-a and (B) IFN-c producing monocytes was significantly higher in patients both at the time
of Tx and at 3 months after Tx compared to healthy controls (p =,0.03). (C) IL-6 production was not different between the groups tested. (D) The
production of IL-1b was significantly increased in patients at the time of Tx compared to healthy controls. (E) The percentage of IL-10 producing
monocytes was significantly higher 3 months after Tx compared to both healthy controls and recipients at the time of Tx. Healthy controls (n = 14;
n = 9 for IL-10), recipients at Tx (n = 15; n = 10 for IL-10), and 3 months post-Tx (n = 11; n = 7 for IL-10).
doi:10.1371/journal.pone.0070152.g004
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zoledronic acid [38]. These data are in line with our finding that
human monocytes can produce IFN-c. Also the percentage of IL-
1b positive monocytes was found to be significantly higher at the
time of Tx. In contrast to TNF-a and IFN-c however, 3 months
after Tx the percentage of IL-1b positive monocytes was back to
healthy control levels. The increase in the percentage of
monocytes producing pro-inflammatory cytokines could be related
to the increased percentage of intermediate and non-classical
monocytes. These monocytes are believed to be the main
producers of TNF-a as shown by the reduction in TNF-a
production after depletion of CD16+ monocytes in vitro [19],
although the possibility that different monocyte subsets in
transplant recipients may behave differently from those in healthy
controls upon activation cannot be ruled out.
TNF-a, and IFN-c are dominant pro-inflammatory cytokines
involved in transplant rejection [39,40]. De Serres et al. demon-
strated that secretion of pro-inflammatory cytokines IL-1b, IL-6
and TNF-a by circulating monocytes is associated with transplant
glomerulopathy in kidney transplant recipients, indicating a
pivotal role for monocytes in chronic post-transplant inflammation
[41]. Furthermore, monocytes of liver transplant recipients who
experienced rejection showed an enhanced capacity to produce
TNF-a and IL-6 compared to patients who did not develop
rejection [42]. IL-6 was shown to be a main driver of chronic
cardiac allograft dysfunction [43]. In murine transplant models,
high IFN-c gene expression levels were associated with rejection
[44] and IFN-c2/2 mice were incapable of rejecting MHCII
incompatible grafts [45]. In humans, high pre-transplant IFN-c
plasma levels and IFN-c production during a mixed lymphocyte
reaction were associated with acute rejection episodes [46,47] and
a predictor of long term graft function [48]. IFN-c mRNA was
significantly higher in patients with pronounced clinical glomer-
ulitis compared to patients with subclinical glomerulitis and
patients without any histological abnormalities [49].
Surprisingly, the percentage of IL-10-producing monocytes
appeared to be significantly increased at 3 months post-Tx,
although the results indicate that not all recipients have an
increased IL-10 producing capability. This increase in IL-10
production in combination with the increased expression of pro-
inflammatory cytokines might be attributed to a triggered innate
immune system. Accordingly, Cartwright et al. observed that high
production of IL-10 in a mixed lymphocyte reaction pre-Tx was
strongly associated with rejection [46].
In conclusion, our data point to a prolonged shift towards pro-
inflammatory intermediate and non-classical monocyte subsets in
kidney transplant recipients, paralleled by an increased potential of
cytokine production, despite recovered kidney function and the
use of potent immunosuppressive drugs. The question arises
whether skewing of the innate immune system towards a more
pro-inflammatory set-point facilitates the occurrence of acute and/
or chronic rejection. Further studies are needed to elucidate the
functional implications of these alterations.
Supporting Information
Figure S1 TNF-a producing monocytes in kidney trans-
plant recipients. Production of TNF-a was tested after no
stimulation or combined stimulation of freshly isolated PBMCs of
healthy controls (A and B), recipients at the time of Tx (D and E)
and recipients at 3 months after Tx (G and H) with IFN-c and
LPS in the presence of golgiplug. (C, F, I) Corresponding
histograms for unstimulated (dashed line) and stimulated (solid
line) cells. The monocyte population was determined based on
forward/sideward scatter, lack of expression of CD3, CD20 and
CD56 and expression of CD14 and CD16. Representative FACS
plots of intracellular cytokine production are shown.
(TIF)
Figure S2 IFN-c producing monocytes in kidney trans-
plant recipients. Production of IFN-c was tested after no
stimulation or combined stimulation of freshly isolated PBMCs of
healthy controls (A and B), recipients at the time of Tx (D and E)
and recipients at 3 months after Tx (G and H) with IFN-c and
LPS in the presence of golgiplug. (C, F, I) Corresponding
histograms for unstimulated (dashed line) and stimulated (solid
line) cells. The monocyte population was determined based on
forward/sideward scatter, lack of expression of CD3, CD20 and
CD56 and expression of CD14 and CD16. Representative FACS
plots of intracellular cytokine production are shown.
(TIF)
Figure S3 IL-6 producing monocytes in kidney trans-
plant recipients. Production of IL-6 was tested after no
stimulation or combined stimulation of freshly isolated PBMCs
of healthy controls (A and B), recipients at the time of Tx (D and
E) and recipients at 3 months after Tx (G and H) with IFN-c and
LPS in the presence of golgiplug. (C, F, I) Corresponding
histograms for unstimulated (dashed line) and stimulated (solid
line) cells. The monocyte population was determined based on
forward/sideward scatter, lack of expression of CD3, CD20 and
CD56 and expression of CD14 and CD16. Representative FACS
plots of intracellular cytokine production are shown.
(TIF)
Figure S4 IL-1b producing monocytes in kidney trans-
plant recipients. Production of IL-1b was tested after no
stimulation or combined stimulation of freshly isolated PBMCs of
healthy controls (A and B), recipients at the time of Tx (D and E)
and recipients at 3 months after Tx (G and H) with IFN-c and
LPS in the presence of golgiplug. (C, F, I) Corresponding
histograms for unstimulated (dashed line) and stimulated (solid
line) cells. The monocyte population was determined based on
forward/sideward scatter, lack of expression of CD3, CD20 and
CD56 and expression of CD14 and CD16. Representative FACS
plots of intracellular cytokine production are shown.
(TIF)
Figure S5 IL-10 producing monocytes in kidney trans-
plant recipients. Production of IL-10 was tested after no
stimulation or combined stimulation of freshly isolated PBMCs of
healthy controls (A and B), recipients at the time of Tx (D and E)
and recipients at 3 months after Tx (G and H) with IFN-c and
LPS in the presence of golgiplug. (C, F, I) Corresponding
histograms for unstimulated (dashed line) and stimulated (solid
line) cells. The monocyte population was determined based on
forward/sideward scatter, lack of expression of CD3, CD20 and
CD56 and expression of CD14 and CD16. Representative FACS
plots of intracellular cytokine production are shown.
(TIF)
Figure S6 Isotype controls in unstimulated cells ob-
tained from kidney transplant recipients. Representative
FACS plots are shown of the isotype controls for the intracellular
cytokine staining. Isotype controls in unstimulated cells for TNF-a,
IFN-c, IL-6, IL-1b and IL-10 (left side) and cytokine staining in
unstimulated cells for TNF-a, IFN-c, IL-6, IL-1b and IL-10 (right
side).
(TIF)
Figure S7 Isotype controls in IFN-c and LPS stimulated
cells obtained from kidney transplant recipients. Repre-
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sentative FACS plots are shown of the isotype controls for the
intracellular cytokine staining. Isotype controls in IFN-c and LPS
stimulated cells for TNF-a, IFN-c, IL-6, IL-1b and IL-10 (left side)
and cytokine staining in IFN-c and LPS stimulated cells for TNF-
a, IFN-c, IL-6, IL-1b and IL-10 (right side).
(TIF)
Figure S8 Percentage of IFN-c producing monocytes
after stimulation with either IFN-c and LPS or LPS
alone. Production of IFN-c was tested after stimulation of freshly
isolated PBMCs from recipients at time of Tx with either the
combination of IFN-c and LPS or LPS alone in the presence of
golgiplug. The monocyte population was determined based on
forward/sideward scatter, lack of expression of CD3, CD20 and
CD56 and expression of CD14 and CD16. (A) Histogram of IFN-
c production of unstimulated monocytes (dashed line), IFN-c and
LPS stimulated (solid line) and LPS stimulated (dotted line). (B)
The ratio of the percentage of IFN-c producing monocytes with
IFN-c and LPS or LPS stimulation alone compared to the
unstimulated situation was comparable.
(TIF)
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